olivLaw · US equity research
Intellia Therapeutics, Inc. NTLA
In Vitro & In Vivo Diagnostic Substances · SIC 2835 · Vertical: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Intellia Therapeutics develops therapies that edit genes inside the body using CRISPR, aiming to treat the root cause of severe rare diseases with a single infusion. The company has two candidates in Phase 3, and the planned U.S. launch of lonvo-z for hereditary angioedema is set for the first half of 2027, if approved, while research spending has fallen from the prior year. Reported funds are said to be sufficient for operations at least into 2028.
At the close of 04 Nov 2026, Intellia Therapeutics, Inc. (NTLA) stock was 12.31 USD (+3.79% on the day), with market capitalisation 1.7 bn USD, beta 1.83, 52-week range 8.04–17.84 USD. Latest reported quarter (Q2 2026): revenue of 7.7 m USD (−46.2% YoY), net income of -106.6 m USD, diluted EPS -0.80 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 52.1
- neutral
- Bollinger (20, 2)
- 10.67 – 13.35
- in the upper half of the band · %B 0.61 · band width 22.3%
- SMA 50 / 200
- 12.17 / 13.05
- mixed trend
- MACD (12, 26, 9)
- 0.04 / -0.01
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −3.5% | −1.1% | −2.4 pp | — |
| 3 months | +12.2% | −0.5% | +12.7 pp | — |
| 6 months | −11.1% | +4.4% | −15.5 pp | — |
| Year to date | +36.9% | +12.3% | +24.6 pp | — |
| 1 year | +0.9% | +13.5% | −12.6 pp | −26.8% |
| 3 years | −57.2% | +76.4% | −133.6 pp | −49.4% |
| 5 years | −90.9% | +63.7% | −154.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.1 m | 12.9 m | 16.6 m | 14.2 m | 13.8 m | 23.0 m | 15.0 m | 7.7 m |
| Research & development | 123.4 m | 116.9 m | 108.4 m | 97.0 m | 94.7 m | 88.7 m | 80.7 m | 82.6 m |
| Operating income | -144.8 m | -136.4 m | -120.8 m | -110.0 m | -111.5 m | -98.7 m | -100.5 m | -112.8 m |
| Depreciation & amortisation | 2.6 m | 2.6 m | 2.5 m | 2.5 m | 2.4 m | 2.4 m | 2.2 m | 2.1 m |
| Net income | -135.7 m | -128.9 m | -114.3 m | -101.3 m | -101.3 m | -95.8 m | -96.2 m | -106.6 m |
| Diluted EPS | -1.34 | -1.27 ≈ | -1.10 | -0.98 | -0.92 | -0.83 ≈ | -0.81 | -0.80 |
| Operating cash flow | -84.8 m ≈ | -85.2 m | -148.9 m | -99.6 m ≈ | -76.9 m ≈ | -69.3 m | -117.3 m | -83.1 m ≈ |
| Capex | 1.3 m ≈ | 981.0 k | 735.0 k | 239.0 k ≈ | 29.0 k ≈ | 126.0 k | 79.0 k | 1.8 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.4 m | 43.1 m | 58.0 m | 33.1 m | 52.1 m | 36.3 m | 57.9 m | 67.7 m |
| Revenue YoY | +16.5% | +41.6% | +34.5% | −43.0% | +57.7% | −30.4% | +59.6% | +16.9% |
| Net income | -85.3 m | -474.2 m | -134.2 m | -267.9 m | -474.2 m | -481.2 m | -519.0 m | -412.7 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -280.4% | -1,100.1% | -231.5% | -810.5% | -909.8% | -1,326.5% | -896.8% | -609.9% |
| Free cash flow | -67.6 m | -110.0 m | -53.5 m | -237.8 m | -346.8 m | -408.1 m | -354.7 m | -395.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 155.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 671.4 m USD
- Total assets
- 842.1 m USD
- Debt / equity
- unavailable
- Current ratio
- 5.08x
- ROE
- -53.5%
- ROA
- -40.6%
- FCF margin
- -585.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 58.0 m | 33.1 m | 52.1 m | 36.3 m | 57.9 m | 67.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 0 | 0 | — | — | — | — | SEC (XBRL)· 24 Feb 2022verified |
| Gross profit | 58.0 m ≈ | 33.1 m ≈ | — | — | — | — | SEC (XBRL)· 24 Feb 2022derived |
| Research & development | 150.4 m | 229.8 m | 420.0 m | 435.1 m | 466.3 m | 388.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -136.6 m | -267.9 m | -458.2 m | -515.3 m | -534.3 m | -441.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 6.3 m | 6.9 m | 7.6 m | 9.0 m | 10.3 m | 9.8 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | -130.3 m ≈ | -261.0 m ≈ | -450.6 m ≈ | -506.3 m ≈ | -524.0 m ≈ | -431.2 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Income tax | — | — | — | — | — | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -134.2 m | -267.9 m | -474.2 m | -481.2 m | -519.0 m | -412.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 56.0 m | 70.9 m | 77.0 m | 88.8 m | 98.8 m | 108.4 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 160.0 m | 123.4 m | 523.5 m | 226.7 m | 189.2 m | 155.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 2.1 m | 2.0 m | 3.8 m | 36.5 m | 8.5 m | 9.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 616.5 m | 769.3 m | 1.2 bn | 998.3 m | 639.9 m | 527.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 15.9 m | 21.0 m | 27.9 m | 32.8 m | 27.4 m | 17.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 676.3 m | 1.3 bn | 1.5 bn | 1.3 bn | 1.2 bn | 842.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 10.5 m | 9.7 m | 5.2 m | 7.5 m | 14.6 m | 20.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 64.3 m | 125.8 m | 126.6 m | 115.2 m | 110.9 m | 103.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | — | — | 284.5 m | 250.8 m | 319.1 m | 170.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 527.1 m † | 1.0 bn † | 1.2 bn † | 1.1 bn † | 872.0 m † | 671.4 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -49.9 m | -225.0 m | -333.3 m | -394.1 m | -348.9 m | -394.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 3.6 m | 12.8 m | 13.6 m | 14.0 m | 5.8 m | 1.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -53.5 m ≈ | -237.8 m ≈ | -346.8 m ≈ | -408.1 m ≈ | -354.7 m ≈ | -395.9 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -214.5 m | -550.8 m | 160.3 m | -31.3 m | 125.6 m | 228.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 371.8 m | 736.7 m | 583.0 m | 130.3 m | 185.7 m | 131.5 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.7 bn USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -672.2% | 33 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 9.1% | 76 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 6.6x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -20.2% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial76/100 · 1/2 factors with a value
- Quality· partial33/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
INTELLIA THERAPEUTICS, INC. (NTLA). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 67.7 m USD in 2025; YoY growth 16.9%; net margin -672.2%; ROE -6,424.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 9.1%
- Current ratio: 6.6x
What contradicts it
- FCF yield: -20.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
In Vitro & In Vivo Diagnostic Substances (SIC 2835) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IDXXIdexx Laboratories Inc | 55.0 bn | 47.1 | 68.9% | 25.4% | +10.4% | −7% / +50% |
| LNTHLantheus Holdings, Inc. | 6.6 bn | 24.5 | 22.2% | 17.7% | +0.5% | +72% / +41% |
| NEOGNeogen Corporation | 2.7 bn | — | -2.7% | -6.3% | −2.7% | +108% / −27% |
| TRIBTrinity Biotech PLC | 2.4 bn | — | — | -51.6% | +8.3% | −80% / −91% |
| CLDXCelldex Therapeutics, Inc. | 2.4 bn | — | -43.9% | -190,220.9% | −78.0% | +11% / −1% |
| NTLAIntellia Therapeutics, Inc. | 1.7 bn | — | -6,424.8% | -672.2% | +16.9% | +1% / −57% |
| QDELQuidelortho Corp | 984.6 m | — | -19.3% | -14.2% | −1.9% | −48% / −79% |
| ACHVAchieve Life Sciences, Inc. | 718.3 m | — | -845.0% | — | unavailable | +43% / +21% |
| MYGNMyriad Genetics, Inc. | 575.8 m | — | -32.5% | -14.0% | −1.6% | −21% / −68% |
| TKNOAlpha Teknova, Inc. | 395.7 m | — | -24.2% | -38.4% | +7.4% | +57% / +261% |
| ICCCImmuCell Corporation | 94.2 m | 138.2 | 2.6% | 2.6% | +4.3% | +114% / +128% |
| IMDXInsight Molecular Diagnostics Inc. | 86.7 m | — | — | -2,955.6% | +115.6% | −57% / −30% |
| BMRABiomerica, Inc. | 8.0 m | — | -113.8% | -115.5% | −16.2% | −27% / −77% |
| CDIOCardio Diagnostics Holdings, Inc. | 4.9 m | — | -75.4% | -44,771.8% | −57.5% | −43% / −97% |
| QCLSQ/C Technologies, Inc. | 3.2 m | — | -155.0% | — | −5.3% | −89% / −100% |
| VNRXVolitionRx Limited | 2.8 m | — | — | -1,043.1% | +40.0% | −97% / −99% |
| VRAXVirax Biolabs Group Ltd | 695.1 k | — | -109.6% | -95,739.2% | −96.0% | −88% / −98% |
| NNNNAnbio Biotechnology | — | 25.0 | 27.0% | 74.1% | +5.6% | −84% / unavailable |
1- and 3-year price returns: for NTLA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Intellia Therapeutics develops therapies that edit genes inside the body using CRISPR, aiming to treat the root cause of severe rare diseases with a single infusion. The company has two candidates in Phase 3, and the planned U.S. launch of lonvo-z for hereditary angioedema is set for the first half of 2027, if approved, while research spending has fallen from the prior year 13. Reported funds are said to be sufficient for operations at least into 2028 3.
SWOT
Strengths
- The company has candidates in Phase 3, being among the first in vivo gene editing programs to reach this stage, and reported positive HAELO data 13.
- Available funds and the recent financing extend the operating runway, which the company says could cover activity at least into 2028 3.
- The company has already built medical and market access teams for launch, which may shorten commercial preparation time 13.
Weaknesses
- Revenue remains small and depends largely on collaborations, especially with Regeneron 13.
- Net losses remain high while commercial spending rises before any approved product exists, which may weigh on results 13.
- The nex-z program was temporarily held, and a patient death in a study drew attention to safety, which may delay development 1.
Opportunities
- An approval of lonvo-z could open access to a patient population whose current treatment is chronic 13.
- If long-term data hold, the one-time therapy could extend the company into other liver diseases 1.
- Collaborations can bring upfront payments, milestones and royalties, which could support funding without further dilution 1.
Threats
- Regulators could request additional data or delay approval, which would push back the commercial launch 13.
- Liver safety could erode physician and patient confidence if new adverse events emerge 13.
- Competition with well-established chronic therapies could slow adoption, especially if payers do not accept the price 1.
Risks
- Uncertain regulatory approvalhigh
No in vivo gene editing therapy has been approved so far, and the lonvo-z application could be delayed or rejected 13.
- Safety of nex-zhigh
A serious liver event in one study led to a clinical hold, and the genomic analysis points to a possible link with an HLA allele 13.
- Dependence on Regeneronmedium
Revenue and costs of the ATTR program depend on the Regeneron collaboration, and a reduction in its contributions could affect results 13.
- Shareholder dilutionmedium
Equity financing could dilute existing shareholders, and the terms of equity instruments may limit their rights 13.
- Market acceptancelow
Physicians and payers may be reluctant toward new and costly therapies, and acceptance of lonvo-z could be slower than expected 1.
Investment thesis
What would need to be true (bull case)
- If lonvo-z is approved and launched in the first half of 2027, the company could become the first to commercialize an in vivo gene editing therapy, supported by positive Phase 3 data 23.
- The HAELO results, with an 87% reduction in attacks, could support rapid adoption if the one-time therapy proves durable 3.
- Recent financing and a funding runway into 2028 could let the company complete its launch without being forced into a sale of assets 3.
What would break the thesis
- Approval of lonvo-z could slip if FDA requests additional data or if the BLA submission is pushed beyond the second half of 2026 23.
- The nex-z program remains partly on hold, and the genomic findings could lead to further restrictions on eligible patients 13.
- Revenue is low and depends on Regeneron, and high net losses could persist until commercial launch 13.
What to watch
- FDA acceptance of the lonvo-z BLAsecond half 2026
- Commercial launch of lonvo-z in the U.S., if approvedfirst half 2027
- Completion of enrollment in the MAGNITUDE-2 study of nex-zsecond half 2026
- Resolution of the FDA clinical hold on the MAGNITUDE study of nex-znext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Intellia Therapeutics, Inc. is a biopharmaceutical company focused on CRISPR gene editing and other core technologies, including oligonucleotides and lipid nanoparticles. Its lead candidates, lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis, are the first in vivo genome editing candidates to enter Phase 3 development 1. Revenue currently comes almost entirely from collaborations, mainly with Regeneron, rather than product sales 12.
The strategy has four parts: advancing lead candidates through late-stage trials, building a fully integrated commercial infrastructure in the United States, expanding the pipeline with proprietary technologies, and partnering to extend the reach of the technology 1. Launch preparations for lonvo-z already include field medical teams and payer discussions, and the company notes that approval must come before any sales 13.
In 2026 the company reported positive data from the Phase 3 HAELO study and said it expects FDA to accept the lonvo-z BLA in the second half of 2026 23. For nex-z, the MAGNITUDE studies were affected by a temporary FDA clinical hold, and enrollment was reinitiated in the second quarter of 2026 13.
Segments
Lonvo-z (hereditary angioedema)
Lonvo-z is a one-time CRISPR candidate designed to inactivate the KLKB1 gene in the liver. In the HAELO study, attacks fell 87% versus placebo over the six-month efficacy period, and the company said it is preparing a BLA submission 3. The study enrolled 80 patients, and it is currently the most advanced program 1.
Nex-z (ATTR amyloidosis)
Nex-z aims to inactivate the TTR gene in the liver to reduce TTR protein production, with the Phase 3 MAGNITUDE trial planned for about 1,200 adults with cardiomyopathy 1. The FDA placed the program on temporary clinical hold after a serious liver event, and the company announced a genomic analysis linking liver enzyme elevations to one HLA allele 13. Regeneron shares about 25% of costs and profits for this program 1.
Market context
Gene editing therapies are a new field in which no in vivo gene editing therapy has yet been approved in the United States or the European Union, according to the company 1. The hereditary angioedema market already includes more than ten approved products, and in a company-sponsored market study many patients and physicians expressed interest in a one-time therapy 1.
The company estimates about 7,000 U.S. patients with hereditary angioedema are being treated, and about 50,000 people worldwide have hereditary ATTR amyloidosis 1. For wild-type ATTR cardiomyopathy, global prevalence is estimated between 250,000 and 500,000 people 1.
Trends
- In vivo gene editing as a new modalitytailwind
The company argues clinical data show in vivo gene editing can offer a one-time treatment, which could change how rare diseases are treated. If these results hold at scale, interest in one-time therapies could grow 13.
- Regulatory familiarityheadwind
Regulators including FDA have limited experience with in vivo CRISPR therapies, which may lengthen review or require additional data 1.
- Development cost pressuremixed
Research and development spending fell in 2025 after a workforce reduction, but commercial costs are rising as launch preparations proceed, changing the spending mix 12.
- Capital markets and fundingmixed
The company has raised funds through public offerings and at-the-market programs, which could dilute existing shareholders but extends the funding runway if the launch succeeds 13.
Competitive position
In hereditary angioedema, more than ten products are approved in the U.S. as long-term prophylaxis or on-demand treatments, given by injection or orally 1. In ATTR amyloidosis, three therapies are approved for ATTRv polyneuropathy and three for ATTR cardiomyopathy, all requiring chronic dosing 1.
The company's stated advantage is that a single dose could replace chronic treatment, though this depends on confirming long-term results and on acceptance by physicians and payers 1. An ex vivo CRISPR therapy is approved in the U.S. and EU, but that does not mean the in vivo market is already open 1.
- Approved hereditary angioedema therapies
More than ten products approved in the U.S., given chronically or on demand, competing directly with lonvo-z.
- Approved ATTRv polyneuropathy therapies
Three treatments approved in the U.S., requiring chronic lifetime administration.
- Approved ATTR cardiomyopathy therapies
Three treatments approved in the U.S., which improve outcomes without stopping progressive disease.
- Approved ex vivo CRISPR therapy
One CRISPR-edited ex vivo therapy is approved in the U.S. and EU, but no in vivo therapy is approved yet.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study AdvancesYahoo Finance — News · 19 Sept 2026 · EN
- Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?Yahoo Finance — News · 10 Sept 2026 · EN
SEC filings
- Current report08 Sept 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report04 Sept 2026Material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report15 Jun 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report10 Jun 2026Shareholder vote
- Quarterly report11 May 2026
- Current report11 May 2026Results of operations · Financial statements and exhibits
- Current report30 Apr 2026Material agreement · Results of operations · Financial statements and exhibits
- Proxy statement30 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Intellia Therapeutics, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Intellia Therapeutics, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Intellia Therapeutics, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.